TAIPEI, Taiwan — Anbogen Therapeutics, Inc., a clinical-stage oncology company specializing in precision medicine, announced today the signing of a Memorandum of Understanding (MOU) for a strategic investment with GEM YIELD BAHAMAS LIMITED, a member of the Global Emerging Markets (GEM) group.
Following a comprehensive evaluation of Anbogen’s R&D pipeline, GEM has committed a strategic investment facility of up to US$150 million. This partnership underscores international capital markets' recognition of Anbogen’s innovation in small-molecule precision oncology. The company intends to utilize this strategic investment facility to accelerate clinical trials and expand its R&D pipeline, further strengthening its competitive position in the global oncology drug development landscape.

ABT-301 (Imofinostat): A Differentiated Epigenetic TME Reprogrammer
Anbogen’s lead candidate, Imofinostat (ABT-301), is a selective Class I Histone Deacetylase inhibitor (HDACi) designed as an Epigenetic Tumor Microenvironment (TME) Reprogrammer. Its unique mechanism of action converts "cold" tumors into "hot" tumors, significantly enhancing the efficacy of immune checkpoint inhibitors.
By positioning itself at the intersection of precision oncology and immuno-oncology (IO), ABT-301 offers a highly differentiated clinical value proposition. A global multicenter Phase 1/2 trial (NCT07244705) evaluating ABT-301 in a triple-combination therapy for advanced colorectal cancer is currently underway.

Breakthrough Potential in Pancreatic Cancer
In the field of high-mortality pancreatic cancer, recent research indicates that ABT-301 can modulate the HDAC3-NRF2 signaling pathway to improve chemotherapy response in KRAS-mutant pancreatic ductal adenocarcinoma (PDAC). This pathway is a known driver of drug resistance; by effectively intervening, ABT-301 has the potential to sensitize patients to existing chemotherapies and address a critical unmet medical need. These findings were officially presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.